RA
BBOT

Royce & Associates’s BridgeBio Oncology BBOT Stock Holding History

Royce & Associates’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Sell
384,941
-251,581
-40% -$2.1M 0.02% 563
2026
Q1 		$5.7M Buy
+636,522
New +$6.83M 0.06% 444

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates's BBOT Position: Q2 2026 in Review

Royce & Associates reduced its BridgeBio Oncology (BBOT) stake by 40% in Q2 2026, selling an estimated $2.1M and leaving 384,941 shares worth $2.93M. The position accounts for 0.02% of the portfolio, ranked #563.

Royce & Associates first reported a position in BBOT in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.7M in Q1 2026. 66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Royce & Associates held 384,941 shares of BridgeBio Oncology worth $2.93M as of Q2 2026.
  • Royce & Associates sold 251,581 BridgeBio Oncology shares in Q2 2026, an estimated $2.1M.
  • BridgeBio Oncology made up 0.02% of Royce & Associates's portfolio in Q2 2026, its #563 holding.
  • Royce & Associates first reported a position in BridgeBio Oncology in Q1 2026 and has held it in 2 quarters since.
  • Royce & Associates's BridgeBio Oncology position peaked at $5.7M in Q1 2026.
  • 66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.